[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470811":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":37,"centralContacts":41,"locations":50,"responsibleParty":66,"collaborators":36,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":36,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":36,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":53,"whyStopped":36,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"CAR-NK cell therapy group","EXPERIMENTAL","Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell therapy group.",[13],"Biological: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells",{"label":15,"type":10,"description":16,"interventionNames":17},"IL7\u002FCCL19 secreting CAR-NK cell therapy group","Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the IL7\u002FCCL19 secreting CAR-NK cell therapy group.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"PD1\u002FPDL1\u002FCTLA4-scfv secreting CAR-NK cell therapy group","Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the PD1\u002FPDL1\u002FCTLA4-scfv secreting CAR-NK cell therapy group.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"CAR-NK cell plus CBD therapy group","Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus CBD therapy group.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"CAR-NK cell plus NAD therapy group","Appropriate patients who could benefit from the Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cell therapy against solid cancers are chosen to be the CAR-NK cell plus NAD therapy group.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"BIOLOGICAL","Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells","Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with\u002For without IL7\u002FCCL19 and\u002For scfv against PD1\u002FCTLA4\u002FLag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.\n\nIn some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy.",[23,27,9,15,19],null,[38],{"name":39,"affiliation":5,"role":40},"Zhenfeng Zhang, MD, PHD","PRINCIPAL_INVESTIGATOR",[42,46],{"name":39,"role":43,"phone":44,"phoneExt":36,"email":45},"CONTACT","+862039195966","zhangzhf@gzhmu.edu.cn",{"name":47,"role":43,"phone":48,"phoneExt":36,"email":49},"Bingjia He, MD","+862039195965","464677938@qq.com",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":36,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"The Second Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":59,"coordinates":60},"Point",[61,62],113.25,23.11667,{"lat":62,"lon":61},[65],{"name":39,"role":43,"phone":36,"phoneExt":36,"email":36},{"type":67,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100470811","phase-1-cldn6gpc3mesothelinaxl-car-nk-cell-therapy-for-advanced-solid-tumors-100470811",false,"NCT05410717","CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-CAR-NK Cell Therapy for Advanced Solid Tumors","Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-CAR-NK in Patients With CLDN6\u002FGPC3\u002FMesothelin\u002FAXL-positive Advanced Solid Tumors","Inclusion Criteria:\n\n1. patients with advanced ovarian cancer or other cancers with expression of claudin6.\n2. Life expectancy \\>12 weeks\n3. Adequate heart,lung,liver,kidney function\n4. Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6, GPC3, Mesothelin, or AXL-CAR determined by flow-cytometry and killing of claudin6-positive targets greater than or equal to 20% in cytotoxicity assay\n5. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent. -\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Tumor size more than 25cm;\n3. Severe virus infection such as HBV,HCV,HIV,et al\n4. Known HIV positivity\n5. History of liver\u002Frenal transplantation\n6. Active infectious disease related to bacteria, virus,fungi,et al\n7. Other severe diseases that the investigators consider not appropriate;\n8. Pregnant or lactating women\n9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday)\n10. Other conditions that the investigators consider not appropriate. -","ALL","18 Years","75 Years",{"count":79,"type":80},200,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)",[86,87,88,89],"Stage IV Ovarian Cancer","Testis Cancer, Refractory","Endometrial Cancer Recurrent","CAR NK",[91,92,89,93,94,95,96,97,98,99,100,101,102],"Solid tumor","Claudin6","GPC3","Mesothelin","AXL","Cannabidiol","Nicotinamide adenine dinucleotide","IL7","CCL19","PD1 antibody","PDL1 antibody","CTLA1 antibody","2024-06-22",{"date":105,"type":106},"2024-06-25","ACTUAL",{"date":108,"type":106},"2022-06-01",{"date":110,"type":80},"2036-05-31",{"name":5,"class":6},1]